Description
An FXR agonist; enhances the interaction between the human FXR ligand binding domain and the SRC-1 peptide in an HTRF coactivator interaction assay (EC50 = 0.2 nM); increases expression of the FXR target genes BSEP and SHP and decreases expression of CPY8B1 in rat liver in a dose-dependent manner, as well as increases expression of SHP and FGF15 in rat ileum; reduces triglyceride levels by 79% in rat serum at 0.3 mg/kg; reduces fibrosis, inflammation, and steatosis in a mouse model of NASH
Formal name: 2-[(3-endo)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl]methoxy]-8-azabicyclo[3.2.1]oct-8-yl]-4-fluoro-6-benzothiazolecarboxylic acid
Synonyms: LJN452
Molecular weight: 603.6
CAS: 1383816-29-2
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Endocrinology & Metabolism|Bile Acids & Microbiome||Research Area|Endocrinology & Metabolism|Hormones & Receptors|FXRs & LXRs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH